Publications by authors named "K P Zimmer"
Article Synopsis
- Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), poses a significant risk to patients undergoing craniotomies, especially due to prolonged surgery duration.
- A study involving 1,759 craniotomy patients from 2009 to 2023 showed that postoperative D-dimer testing significantly improved DVT detection rates, while using intermittent pneumatic compression (IPC) dramatically reduced VTE occurrences.
- Results indicated that without routine D-dimer checks, nearly 20% of patients faced the risk of undetected thrombosis, emphasizing the importance of D-dimer analysis and IPC in reducing VTE risk during craniotomy procedures.
Vipera berus (V. berus) bites are associated with high morbidity, including kidney injury, in dogs. Although antivenom is often used and perceived effective to treat this type of snakebite, it is costly and associated with adverse events and specific diagnostics for this type of snakebite are lacking.
View Article and Find Full Text PDFAgroindustrial wastes are generated daily and seem to be rich in bioactive molecules. Thus, they can potentially be used as source of compounds able to control bacterial biofilms. We investigated the potential of extracts from the residues of rice and grape to combat clinically important bacterial biofilms.
View Article and Find Full Text PDFPurpose: To investigate if the cytokine profile in the aqueous humor (AH) of cataract patients varies according to cataract type and severity.
Methods: This prospective study included 397 eyes of 397 patients (median age, 76 years; range, 30-94 years) who underwent standard small-incision phacoemulsification surgery. Cataracts were graded using the LOCS III system: mild (≤3), moderate (3.
Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a protein that regulates low-density lipoprotein (LDL) cholesterol metabolism by binding to the hepatic LDL receptor (LDLR), ultimately leading to its lysosomal degradation and an increase in LDL cholesterol (LDLc) levels. Treatment strategies have been developed based on blocking PCSK9 with specific antibodies (alirocumab, evolocumab) and on blocking its production with small regulatory RNA (siRNA) (inclisiran). Clinical trials evaluating these drugs have confirmed their high efficacy in reducing serum LDLc levels and improving the prognosis in patients with atherosclerotic cardiovascular diseases.
View Article and Find Full Text PDF